We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $8.89 · 9 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation ACCESS Newswire
2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out ACCESS Newswire
AQST Stock Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
AQST Stock Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect ACCESS Newswire
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com Investing.com South Africa
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.12 | — | — | $11.56M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.24 | — | — | $8.72M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.32 | — | — | $45.69M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.19 | — | — | $32.15M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 11. 07. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2025. 10. 09. | JMP Securities | — | Maintain | Market Outperform → Market Outperform | — | JMP Securities: Market Outperform |
| 2025. 09. 08. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2025. 06. 17. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 05. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 04. 02. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,139,404 | $4.73B | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 381,120 | $2.46B | 0.00% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 283,734 | $1.18B | 0.00% | — | New position |